HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Novan, Inc. (NOVN)
0.5052  -0.0348  (-6.44%) 07-07 14:51
Open: 0.525 High: 0.5388
Pre.close: 0.54 Low: 0.4909
Volume: 10,915,154 Ave vol: 14,504,850
52w High: 3.72 52w Low: 0.215
MA(50): 0.47 MA(200): 0.631
EPS: -1.04 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novan.com
Market Cap (M): 41
Shares Out (M): 81
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.
Technical analysis
Overall: Neutral
MA: Bullish MACD: Bearish
KDJ: Bullish RSI: Bearish
Target 1: 0.82 Target 2: 1.04
Resist 1: 0.70 Resist 2: 0.89
Support 1: 0.39 Support 2: 0.33
Company key metrics
Revenue per Share: 0
Net Income per Share: 0
Cash per Share: 0
Book Value per Share: 0
Price to Sales: 0
Price to Book Value: 0
Earnings Yield: 0
Dividend Yield: 0
Debt to Equity: -2.2232
Debt to Assets: 1.8175
Financial analysis
Price to Book Value: Underperform
Return on Assets: Underperform
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Underperform
Stock Charts
Headline news
Tue, 07 Jul 2020
Novan Inc. (NOVN) is primed for evolution with the beta value of -0.26 - The InvestChronicle

Mon, 06 Jul 2020
Buy or Sell Novan, Inc. (NOVN) Stock Now? Don't Try to Be a Top Gun - The News Heater

Mon, 06 Jul 2020
Novan Inc. (NASDAQ:NOVN) is Waving the Bear Flag - The Oracle Dispatch

Wed, 24 Jun 2020
Novan to Present at Virtual Life Sciences Investor Forum on June 25 - GlobeNewswire

Tue, 23 Jun 2020
Why Novan, Inc. (NOVN) Is in Such attractive Condition: Rise 3.26% - The News Heater

Thu, 25 Jun 2020
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial - GlobeNewswire

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.